European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma

By: via Benzinga
Exelixis, Inc. (NASDAQ: EXEL) today announced that the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.